JP2023519959A5 - - Google Patents
Info
- Publication number
- JP2023519959A5 JP2023519959A5 JP2022559484A JP2022559484A JP2023519959A5 JP 2023519959 A5 JP2023519959 A5 JP 2023519959A5 JP 2022559484 A JP2022559484 A JP 2022559484A JP 2022559484 A JP2022559484 A JP 2022559484A JP 2023519959 A5 JP2023519959 A5 JP 2023519959A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- transdermal patch
- weight
- dextromethorphan
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001607P | 2020-03-30 | 2020-03-30 | |
| US63/001,607 | 2020-03-30 | ||
| PCT/US2021/024572 WO2021202329A1 (en) | 2020-03-30 | 2021-03-29 | Transdermal delivery of dextromethorphan |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519959A JP2023519959A (ja) | 2023-05-15 |
| JP2023519959A5 true JP2023519959A5 (https=) | 2024-04-03 |
| JP7798361B2 JP7798361B2 (ja) | 2026-01-14 |
Family
ID=77928529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559484A Active JP7798361B2 (ja) | 2020-03-30 | 2021-03-29 | デキストロメトルファンの経皮送達 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240216358A1 (https=) |
| EP (1) | EP4125902A4 (https=) |
| JP (1) | JP7798361B2 (https=) |
| KR (1) | KR20220161416A (https=) |
| CN (1) | CN115996709A (https=) |
| AU (1) | AU2021249031A1 (https=) |
| CA (1) | CA3173322A1 (https=) |
| IL (1) | IL296624A (https=) |
| TW (1) | TW202203921A (https=) |
| WO (1) | WO2021202329A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12569479B2 (en) | 2016-05-25 | 2026-03-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| EP4255433A4 (en) | 2020-12-01 | 2024-05-29 | Antecip Bioventures II LLC | BUPROPION AND DEXTROMETHORPHAN FOR REDUCING THE RISK OF SUICIDE IN DEPRESSED PATIENTS |
| IT202100029225A1 (it) * | 2021-11-18 | 2023-05-18 | Capietal Italia S R L | Miscela comprendente un cannabidiolo CBD, un beta-cariofillene BCP e un furanodiene, per uso in un metodo di trattamento del dolore neuropatico periferico |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US12036191B1 (en) * | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12194036B2 (en) | 2022-07-07 | 2025-01-14 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| TW202430177A (zh) * | 2022-10-06 | 2024-08-01 | 美商神經治療股份有限公司 | 右旋美索芬之經皮輸送 |
| CN119700641A (zh) * | 2025-02-26 | 2025-03-28 | 深圳市药欣生物科技有限公司 | 舌下施用的右美沙芬药物组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2198390C (en) * | 1994-09-14 | 2009-08-11 | James E. Garbe | Matrix for transdermal drug delivery |
| SE9601528D0 (sv) * | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as antitissue agent |
| US5985317A (en) * | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
| CA2289190A1 (en) * | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| US20060223786A1 (en) * | 2005-04-01 | 2006-10-05 | Smith David J | Transdermal pain control method and device |
| ATE481096T1 (de) * | 2005-04-06 | 2010-10-15 | Adamas Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
| JP2011526889A (ja) * | 2008-06-30 | 2011-10-20 | アフギン ファーマ，エルエルシー | 局所局部的神経作用療法 |
| AU2011331511C1 (en) * | 2010-11-17 | 2018-01-18 | Hexal Ag | Transdermal therapeutic system comprising buprenorphine |
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
| CA3097189A1 (en) * | 2018-04-25 | 2019-10-31 | Shinkei Therapeutics Llc | Tetrabenazine transdermal delivery device |
-
2021
- 2021-03-29 EP EP21779317.3A patent/EP4125902A4/en active Pending
- 2021-03-29 US US17/915,687 patent/US20240216358A1/en active Pending
- 2021-03-29 WO PCT/US2021/024572 patent/WO2021202329A1/en not_active Ceased
- 2021-03-29 IL IL296624A patent/IL296624A/en unknown
- 2021-03-29 TW TW110111395A patent/TW202203921A/zh unknown
- 2021-03-29 CN CN202180039287.7A patent/CN115996709A/zh active Pending
- 2021-03-29 AU AU2021249031A patent/AU2021249031A1/en active Pending
- 2021-03-29 JP JP2022559484A patent/JP7798361B2/ja active Active
- 2021-03-29 CA CA3173322A patent/CA3173322A1/en active Pending
- 2021-03-29 KR KR1020227037539A patent/KR20220161416A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519959A5 (https=) | ||
| JP6845162B2 (ja) | ケタミン経皮送達システム | |
| JP7798361B2 (ja) | デキストロメトルファンの経皮送達 | |
| US20220395469A1 (en) | Transdermal drug delivery system for ketamine | |
| RU2408368C2 (ru) | Препараты соли бупропиона с модифицированным высвобождением | |
| JP2022060428A (ja) | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム | |
| RU2007122410A (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda-рецептора, способ введения такого nmda-антагониста субъекту | |
| US8017146B2 (en) | Transdermal delivery system with two superimposed adhesive layers having different affinities to the active substance comprised | |
| JP2002510600A (ja) | メチルフェニデートで注意欠乏障害及び注意欠乏／活動亢進障害を治療する組成物及び方法 | |
| JP2022087276A (ja) | メマンチン経皮送達システム | |
| JP2020536953A5 (https=) | ||
| US20120171297A1 (en) | Threo-dops controlled release formulation | |
| SK138095A3 (en) | Transdermal therapeutic system for the administration of serotonin agonists | |
| US9408802B1 (en) | Seven day drug in adhesive transdermal delivery | |
| CA2598406C (en) | Method for a treatment with a medicament combination and medicament combinations suitable for the same | |
| EP3522843B1 (en) | Pramipexole transdermal delivery system and uses thereof | |
| JP2022540917A (ja) | 治療的処置のためのガボキサドール含有医薬製剤 | |
| TW202430177A (zh) | 右旋美索芬之經皮輸送 | |
| HK40129313A (zh) | 右美沙芬的经皮递送 | |
| HK40025664A (en) | Transdermal drug delivery system for ketamine | |
| HK1052287A1 (en) | Minimizing adverse experience associated with oxybutynin therapy |